cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Emergency Suturing with Absorbable Versus Non-absorbable Suture Material in a Pediatric Population

The investigators recruit patients admitted to the Pediatric Emergency Department of the Geneva's University Hospital with open wounds needing suture. The patients are treated with absorbable versus non-absorbable suture material according to randomization.

Outcomes are:

1. infection rate at the first follow-up (between 4 and 14 days, depending on the sutured site and defined by protocol)
2. scar appearance at a 6-months follow-up.

The investigators recruit patients admitted to the Pediatric Emergency Department of the Geneva's University Hospital with open wounds needing suture. The patients are treated with absorbable versus non-absorbable suture material according to randomization.

After obtaining the patient's/parent's consent and randomization, the suture material will be provided.

Selection of the size of the thread and the date of the first follow-up are determined as follows:

* Face: Thread size 5-0 to 7-0, first follow-up 4-7 days
* Torso/back: Thread size 4-0 or 5-0, first follow-up 10-14 days
* Arms: Thread size 4-0 or 5-0, first follow-up 7- 10 days
* Hand: Thread size 5-0 or 6-0, first follow-up 7-10 days
* Legs: Thread size 4-0 or 5-0, first follow-up 7-14 days

The patients are examined by in the outpatient wound clinic by specialised nurses under medical supervision at the first follow-up, and at six months by one of the investigators.

Outcomes:

1. infection rate at the first follow-up (between 4 and 14 days, depending on the sutured site and defined by protocol)
2. scar appearance at a 6-months follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Patient younger than 16 years of age with a wound requiring suture

Exclusion Criteria:

* Deep wounds with lesions of subcutaneous structures (tendons, nerves, etc.)
* Wounds with tissue loss
* Diabetic patients or patients treated with drugs potentially compromising cicatrization (e.g. steroids, immunosuppressors, etc.)
* Wounds caused by animal or human bites
* Sutures not performed in the emergency room
* Heavily soiled wounds
Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

A Phase III, multi-center, randomized, controlled study designed to demonstrate the efficacy and safety of Cyclosporine Inhalation Solution (CIS)in improving survival and preventing bronchiolitis obliterans syndrome (BOS) when given prophylactically to lung transplant recipients in addition to their standard immunosuppressive regimen.


Eligibility Criteria:
Inclusion Criteria:

* A recipient of a single or double lung transplant (including heart-lung transplant)
* Age 18 years or older
* Able to produce a forced expiratory volume in one second (FEV1) of greater than one liter at randomization
* Eligible subjects must be enrolled within 70 days after receiving a lung transplant
* Clinical status sufficiently stable to enable routine post-transplant bronchoscopy with bronchoalveolar lavage (BAL) and chest X-ray (or equivalent i.e., chest computerized tomogram (CT)) prior to screening

Exclusion Criteria:

* Lung re-transplantation
* Documented allergy to propylene glycol and/or cyclosporine
* Documented respiratory or anastomotic infections unless on appropriate antimicrobial therapy with evidence of clinical response
* Women who are pregnant, wishing to become pregnant, or unwilling to use appropriate birth control to avoid becoming pregnant
* Women who are breastfeeding
* Clinically significant bronchial stenosis unresponsive to dilation and/or stenting
* Malignancies diagnosed within one year prior to screening (with the exception of non-melanomatous skin cancers)
Pharmaceutical Consultation at Hospital Discharge and Adherence to Anti-infective Treatment

The main objective of this study is to evaluate the impact of a pharmaceutical consultation at the time of hospital discharge on the adherence of patients ; non-adherence is determined by the following criteria:

As concerns prescribed anti-infectious treatments, at least one of the following 4 criteria is true:

1. . the patient did not go and get his/her treatment at the pharmacy;
2. . the number of treatment units dispensed by the pharmacy is \< the number of treatment units prescribed;
3. . the patient stopped taking a treatment before the recommended time, or continued taking a treatment after the recommended time;
4. . the number of treatment units taken by the patient (self-declaration) is \< or \> to the number of units prescribed.

The secondary objectives of this study are :

A- To assess the percentage of patients who obtained their anti- infective pharmaceuticals

B- To evaluate the ratio of the number of units of anti- infective drugs dispensed by the pharmacy over the number of units of anti- infective drugs prescribed

C- To determine the ratio of the number of premature discontinuations of anti -infective treatments over the number of lines of anti -infective treatments prescribed

D- Evaluate the ratio of the number of units actually taken by the patient (based on a self-declaration) over the number of units of anti- infective drugs prescribed

E- To measure the comprehension concerning anti- infective treatments after returning home (based on a quiz)

F- To determine the risk factors for non- adherence to anti- infective therapy based on the characteristics of the study population

G- Assess patient satisfaction concerning a pharmaceutical consultation at hospital discharge (questionnaire)

H- Assess the impact of a pharmaceutical consultation on primary non-adherence (criteria 1 and 2) and secondary non- adherence (criteria 3 and 4)

Eligibility Criteria:
Inclusion Criteria:

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* The patient is hospitalized in the Infectious and Tropical Diseases department of the Nîmes University Hospital, and is scheduled for hospital discharge with one or more pharmaceutical prescriptions for anti-infectious treatments

Exclusion Criteria:

* The patient is participating in another study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* The patient resides in a care establishment, or has home medical/nursing service
* The patient is suffering from chronic infection (\>4 weeks of treatment required)
* The patient is suffering from handicapping deafness, dementia, or does not have a telephone
* Intravenous, intramuscular or subcutaneous anti-infectious treatments are prescribed
* Prescription of antiretroviral treatments
The Multistrain Probiotic OMNi-BiOTiC® Active for Upper Respiratory Tract Infections in Older People

The goal of this randomised controlled trial is to determine the effect of consuming a multistrain probiotic OMNi-BiOTiC® Active to shorten the incidence and duration of acute upper respiratory tract infections (URTIs) in older people. The main questions it aims to answer is:

* Is the multistrain probiotic OMNi-BiOTiC® Active effective in reducing the incidence of URTIs in older people?
* Is the multistrain probiotic OMNi-BiOTiC® Active effective in reducing the duration of URTIs in older people?
* Is the multistrain probiotic OMNiBiOTiC® Active effective in changing selected immunological blood parameters in older people? Researchers will compare the probiotic group and the placebo group to see if the incidence or duration of URTIs are significant among the groups.


Eligibility Criteria:
Inclusion Criteria:

* 65 years or older at the signing of the written consent form
* ability of participant to eat independently
* ability of participant to adhere to all procedures of the clinical study

Exclusion Criteria:

* participants experienced an exacerbation of an existing chronic disease
* participants experienced an exacerbation of metabolic diseases,
* participants with mental incapacity to understand instructions
* participants were prescribed long-term usage of antibiotics.
* participants that changed their eating habits or consumed any probiotics 14 days
* participants with markedly abnormal results of blood tests were excluded.
Pain Relief by Applying TENS on Acupuncture Points During the First Stage of Labour

We aimed to establish the reduction of labor pain by applying TENS at acupuncture points during the first stage of labour, to assess their efficacy, and to ascertain their acceptability.

We conducted a double-blind, placebo-controlled randomised trial involving healthy parturient at term pregnancy using TENS on 4 acupuncture points (Li 4 and Sp 6) (n=50) and the placebo group (n=50). Visual analogue scale (VAS) was used to assess the effect on pain before the application, 30 minutes and 60 minutes after TENS. The objective parameter of outcome was the score of VAS decreased in each groups. A post-partum questionnaire was given 24 hours later to evaluate the satisfaction and the use of this pain relieving method for the next delivery.

Eligibility Criteria:
Inclusion Criteria:

The inclusion criteria were:

* Voluntary informed participation to the study
* An initial wish to deliver without epidural analgesia
* Planned vaginal childbirth (non-obstetrical complicated pregnancy)
* Fetal vertex presentation
* Term pregnancy (\>37 weeks of gestation)
* Apply at 1st stage of labour and excluded if cervical dilatation \> 5 cm
* Age between 20 and 40 years
* Chinese speaking, capable to understand the study
* No experience of pain relief by systemic or epidural anesthesia in previous delivery
* No experience in acupuncture or TENS in other field
* Had no heart disease nor using pace-maker.

Exclusion Criteria:

* Cervical dilatation \> 5 cm
* Experience of pain relief by systemic or epidural anesthesia in previous delivery
* Experience in acupuncture or TENS in other field
* Had heart disease or using pace-maker
Respiratory Exercise Diary in Major Abdominal Surgery

Postoperative pulmonary complications are common and lead to increased morbidity and mortality in patients. These complications are observed especially after major surgical interventions. Breathing exercises performed with or without the use of a device are extremely important in preventing postoperative pulmonary complications. Breathing exercises that increase total lung capacity by encouraging the use of the diaphragm reverse alveolar collapse and postoperative hypoxemia. This study aim to determine the effect of postoperative respiratory exercise diary use in patients undergoing major abdominal surgery on dyspnea, fatigue, respiratory parameters (respiratory rate, SPO2, cough, sputum), early pulmonary complications, spirometry use and functional capacity.The research is planned to be conducted in a single-blind, randomized controlled manner. In the study, 60 patients (30 intervention and 30 control) who underwent major abdominal surgery will be included.Data will be collected using the Patient Introduction Form, Visual Analogue Scale, Medical Research Board Scale, 2-minute walk test, breathing exercise diary and patient follow-up chart.Patients in the intervention and control groups will be visited by the researcher for 3 postoperative days, respiratory parameters, cough, and sputum status will be recorded in the patient follow-up chart, and the use of a respiratory exercise diary will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Undergoing elective surgery
* Receiving general anesthesia
* Having major abdominal surgery (colorectal surgery, gastrectomy, liver resection, pancreatectomy)
* Staying in the general surgery service for at least 3 days after the surgery
* Becoming literate

Exclusion Criteria:

* Psychoactive drug use
* Having Alzheimer's or dementia
* Having chronic respiratory diseases (COPD, asthma)
Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI

A randomized, double-blind, placebo controlled parallel group clinical trial evaluating the effects of acute treatment with a PCSK9 inhibitor (alirocumab) versus placebo on low-density lipoprotein (LDL) in 100 high-risk patients presenting with STEMI and referred for primary PCI.

The objective is to determine the effect of acute, rapid lowering of LDL cholesterol with alirocumab added to high dose statin therapy in patients with STEMI undergoing primary PCI. The hypothesis is that, in patients with STEMI undergoing primary PCI, rapid lowering of LDL cholesterol with a PCSK9 Inhibitor (alirocumab) initiated in the acute setting pre-PCI, will favourably affect LDL cholesterol concentrations compared with placebo.


Eligibility Criteria:
Inclusion Criteria:

* Patients presenting with STEMI defined as both of the following: a) Symptoms of myocardial ischemia lasting for ≥ 30 minutes, and b) Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in two contiguous precordial leads.
* Referred for primary PCI for presenting symptoms.
* Randomized within 12 hours of symptom onset and prior to diagnostic angiography.

Exclusion Criteria:

* Age ≤18 years.
* Pregnancy or breastfeeding.
* Current or planned treatment with a PCSK9 inhibitor.
* Allergy or contra-indication to a PCSK9 inhibitor.
* Killip class ≥2.
* Known Creatinine clearance \<30mL/min.
* Suspected takotsubo / stress-induced cardiomyopathy or acute pericarditis.
* Any other medical, geographic, or social factor making study participation impractical or precluding follow-up.
Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study)

Most studies of labour induction with misoprostol used doses higher than 25mg and intervals of 3-4 hours. We studied a low-dose regime of 25mg misoprostol and compared its efficacy as single dose or double dose with dosing interval of 6 hours to our current regime of 3 mg dinoprostone pessary.

171 women with singleton term pregnancies and modified Bishop score (mBS) ≤ 5 were recruited and randomized into 3 arms: current dinoprostone regime, double dose misoprostol or single dose misoprostol. The primary outcome was the number of women who achieved favourable mBS\>6 or active labour by Day 2. Secondary outcomes were time interval from insert to active labour or delivery, abnormal uterine activity, delivery method and adverse neonatal outcome.

Eligibility Criteria:
Inclusion Criteria:

* singleton pregnancy, cephalic presentation, gestation greater than 37 completed weeks, no known contraindication to vaginal delivery, and Bishop score≤5.

Exclusion Criteria:

* previous caesarean section or other uterine surgery, significant maternal medical/obstetric complication in pregnancy (such as severe pre-eclampsia, significant antepartum haemorrhage), antepartum evidence of fetal compromise (such as fetal growth restriction), previous attempt at cervical priming, contraindication to receiving prostaglandins, including asthma and glaucoma.
Using Tea-based Mouthwash Relieve Stomatitis and Oral Ulcers

The aim of this study is to use a tea-based mouthwash to relieve pain and discomfort in patients with stomatitis and ulcers.

The objective of this study is to use tea as a base, supplemented with licorice to reduce bitterness and astringency, to make mouthwash, and use tea's antioxidant and anti-inflammatory properties to relieve the pain and discomfort of stomatitis and ulcer patients. This study will observe the difference between saliva and oral mucosal cells before and after treatment, to find the mechanism of effective treatment of stomatitis.

Eligibility Criteria:
Inclusion Criteria:

age over 20 years old, male or female

Exclusion Criteria:

patients with oral cavity cancer, oropharyngeal cancer, and active bacterial infection.
Body Composition Changes During Stem Cell Transplantation: The Case Of Lymphoma Patients

Skeletal Muscle Index (SMI) and Visceral Adipose Ratio (VAR) assess body composition changes and disclose malnutrition risk effectively. The aims of the study are to assess prevalence of malnutrition in patients planned for SCT, to characterize changes in body composition (SMI, total adipose tissue and VAR) that occur in the peri transplantation phase, and to identify Waist Circumference (WC) cut off points associated with the metabolic syndrome (MetSyn) in patients with B and T cell Lymphoma.

This study is a retrospective cohort study of patients having B and T cell lymphoma, who underwent SCT in the Bone Marrow Transplantation (BMT) unit at AUBMC. Consecutive patients having B and T lymphoma who underwent SCT at AUBMC will be identified by the research team and will be included as per the below inclusion and exclusion criteria. Starting from June 2016, patients who meet the inclusion criteria will be included in the study up until June 2006.

The radiologist will access the AUBMC PACS system to review PET/CT scans of the identified patients. SMI, visceral, subcutaneous and intramuscular adipose tissues will be established by assessing at the level of L3.

Eligibility Criteria:
Inclusion Criteria:

* Age\>16 years
* Patients having B and T cell lymphoma who have undergone SCT at AUBMC

Exclusion Criteria:

* Patients with a missing pre-SCT PET/ CT scan
* Patients with 2 missing post SCT PET / CT scan
Empowering Parental Caregivers

The goal of this clinical trial was to learn about the feasibility and pilot outcome measures in caregivers of children with spinal cord injury who completed a 7-week problem-solving training web-based group. The main question it aims to answer is: What is the feasibility of a seven-week, occupational therapist-facilitated, web-based support group with problem-solving training for parental caregivers of children with SCI?

Participants participated 1 time a week for seven weeks in a web-based group group:

* learning about the FOCUS problem-solving model
* applying positive coping and problem-solving strategies to current issues.


Eligibility Criteria:
Inclusion Criteria:

* one must be a parent or guardian of a child with a spinal cord injury or disorder, be that child's primary caregiver, and be 18 years or older.

Exclusion Criteria:

* None
Atrioventricular Optimization for Dual Chamber Pacemaker

This study aims to examine the effect of atrioventricular synchrony in AV block patients who received permanent pacemaker. By achieving physiologic ventricular diastolic filling, adjustment of atrioventricular delay of pacemaker might affect the long term outcome of left ventricular function and remodelling. The investigators designed to randomize AV block patients who already have or anticipated to receive pacemaker, into two groups. Patients in intervention group undergo reprogramming AV delay of pacemaker to the best value to increase cardiac output measured by transthoracic echocardiogram and the patients in control group undergo routinely scheduled pacemaker programming. The primary endpoint is improvement of LV systolic function and the secondary endpoint is change in left ventricular volume, cardiac output, BNP, 6-minute walk capacity and NYHA class after one year.

It is well-known that persistent right ventricular apical pacing induces left ventricular dysfunction. The most important risk factor is the ratio of ventricular pacing so the effort to reduce pacing ratio is needed. However, almost 100% ventricular pacing is inevitable in complete atrio-ventricular block patients with implanted pacemaker. Traditionally the ventricular lead of the pacemaker is positioned in right ventricular apex and previous literatures reported that such right ventricular apical pacing impedes physiological ventricular contraction and induces left ventricular contractile dysfunction in long-term. The alternative positions of ventricular lead are right ventricular outflow tract and ventricular septum but the benefits are not yet clearly prooved. Additionally, adjusting atrio-ventricular delay is reportedto affect cardiac output by altering diastolic filling. The investigators aimed to analyze the effect of AV dealy in long-term left ventricular contractile function.

Patients over 19 years old who received or anticipated to receive permanent pacemaker due to AV block are randomized to 1:1 ratio into two groups. Patients in intervention group undergo reprogramming AV delay of pacemaker to the best value to increase cardiac output measured by transthoracic echocardiogram and the patients in control group undergo routinely scheduled pacemaker programming. Patients with underlying LV systolic dysfunction or significant valvular heart disease are excluded. Six-minute walk test, BNP, transthoracic echocardiogram, NYHA class are examined at baseline and after one year.

Eligibility Criteria:
Inclusion Criteria:

* Received or scheduled to receive permanent pacemaker due to AV block

Exclusion Criteria:

* Left ventricular ejection fraction \<50% or Left ventricular end-diastolic diameter\>60mm Significant valvular disease (≥mild)
Assessment of Serum Levels of Adenosine Deaminase and Immunoglobulin E in Patients With Chronic Spontaneous Urticaria

adenosine deaminase activity (ADA) has been reported to be elevated in various diseases such as psoriasis, acne and juvenile idiopathic arthritis. There is no previous studies that assessed ADA in chronic spontaneous urticaria (CSU) .


Eligibility Criteria:
Inclusion Criteria:

* adult patients complaining of CSU and a group of age and sex-matched healthy controls (blood donors).

Exclusion Criteria:

* Pregnancy and lactation.
* Patients with systemic diseases, especially those with autoimmune diseases and infections.
* Patients with skin diseases.
* Patients on medications such as antibiotics, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, anticonvulsants, penicillin, and combined oral contraceptives.